論文

査読有り 筆頭著者 責任著者
2021年11月17日

Clinical Characteristics, Achievement of Secondary Prevention Goals, and Outcomes of Patients with Recurrent Acute Coronary Syndrome.

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • Shuhei Tara
  • Takeshi Yamamoto
  • Shin Sakai
  • Tokuhiro Kimura
  • Kazuhiro Asano
  • Yuhi Fujimoto
  • Reiko Shiomura
  • Junya Matsuda
  • Kosuke Kadooka
  • Kenta Takahashi
  • Toshinori Ko
  • Hideto Sangen
  • Yoshiyuki Saiki
  • Jun Nakata
  • Yusuke Hosokawa
  • Hitoshi Takano
  • Wataru Shimizu
  • 全て表示

88
5
開始ページ
432
終了ページ
440
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1272/jnms.JNMS.2021_88-601

BACKGROUND: Because development of acute coronary syndrome (ACS) worsens the prognosis of patients with coronary artery disease, preventing recurrent ACS is crucial. However, the degree to which secondary prevention treatment goals are achieved in patients with recurrent ACS is unknown. METHODS: 214 consecutive ACS patients were classified as having First ACS (n=182) or Recurrent ACS (n=32), and the clinical characteristics of these groups were compared. Fifteen patients died or developed cardiovascular (CV) events during hospitalization, and the remaining 199 patients were followed from the date of hospital discharge to evaluate subsequent CV events. RESULTS: Patients in the Recurrent ACS group were older than those in the First ACS group (76.8±10.8 years vs 68.8±13.4 years, p=0.002) and had a higher rate of diabetes mellitus (DM) (65.6% vs 36.8%, p=0.003). The rate of achieving a low-density lipoprotein cholesterol (LDL-C) level of <70 mg/dL in the Recurrent ACS group was only 28.1%, even though 68.8% of these patients were taking statins. An HbA1c level of <7.0% was achieved in 66.7% of patients with recurrent ACS who had been diagnosed with DM. Overall, 12.5% of patients with recurrent ACS had received optimal treatment for secondary prevention. CV events after hospital discharge were noted in 37.9% of the Recurrent ACS group and 21.2% of the First ACS group (log-rank test: p=0.004). However, recurrent ACS was not an independent risk factor for CV events (adjusted hazard ratio: 2.09, 95% confidence interval: 0.95 to 4.63, p=0.068). CONCLUSION: Optimal treatment for secondary prevention was not achieved in some patients with recurrent ACS, and achievement of the guideline-recommended LDL-C goal for secondary prevention was especially low in this population.

リンク情報
DOI
https://doi.org/10.1272/jnms.JNMS.2021_88-601
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/33692293
ID情報
  • DOI : 10.1272/jnms.JNMS.2021_88-601
  • PubMed ID : 33692293

エクスポート
BibTeX RIS